Beta is a monetary metric that exhibits how a lot a inventory’s value strikes in comparison with the general inventory market. A beta of 1 means the inventory typically strikes in step with the market. If a inventory has a beta beneath 1, it tends to be much less risky, whereas a beta above 1 suggests it’s extra risky than the market common.
For traders, selecting low-beta shares generally is a good technique to scale back danger and restrict publicity to large market swings. Such shares could present higher stability throughout downturns and assist safeguard portfolios, whereas nonetheless providing the potential for regular long-term development.
Listed beneath are such small shares which have a beta of lower than 1:
J B Chemical compounds & Prescribed drugs Restricted
With a market capitalization of Rs. 26,543.06 crore, the shares of J B Chemical compounds & Prescribed drugs Restricted have been at present buying and selling at Rs. 1,695 per fairness share, down almost 0.70 p.c from its earlier day’s shut value of Rs. 1,706.95.
The inventory carries a one-year beta of 0.52, indicating decrease volatility in comparison with the broader market. The corporate’s ROCE and ROE stand at 25.8 p.c and 20.1 p.c, respectively. J B Chemical compounds & Prescribed drugs Restricted additionally reviews an earnings per share (EPS) of Rs. 44, with a debt-to-equity ratio of 0.01x, reflecting its monetary place.
J B Chemical compounds & Prescribed drugs Restricted was established in 1976 by founder J.B. Mody. The corporate manufactures and markets varied pharmaceutical merchandise, together with tablets, capsules, injections, lotions, and medicines for each home and worldwide healthcare markets throughout a number of international locations globally.
Coming into monetary highlights, J B Chemical compounds & Prescribed drugs Restricted’s income has elevated from Rs. 1,004 crore in Q1 FY25 to Rs. 1,094 crore in Q1 FY26, which has grown by 8.96 p.c. The web revenue has additionally grown by 14.12 p.c from Rs. 177 crore in Q1 FY25 to Rs. 202 crore in Q1 FY26.
Navin Fluorine Worldwide Restricted
With a market capitalization of Rs. 24,473.54 crore, the shares of Navin Fluorine Worldwide Restricted have been at present buying and selling at Rs. 4,777.90 per fairness share, rising almost 0.35 p.c from its earlier day’s shut value of Rs. 4,761.20.
The inventory carries a one-year beta of 0.66, indicating decrease volatility in comparison with the broader market. The corporate’s ROCE and ROE stand at 11.7 p.c and 11.5 p.c, respectively. Navin Fluorine Worldwide Restricted additionally reviews an earnings per share (EPS) of Rs. 71.5, with a debt-to-equity ratio of 0.56x, reflecting its monetary place.
Navin Fluorine Worldwide Restricted was established in 1967. The corporate manufactures specialty fluorochemicals, together with refrigeration gases, inorganic fluorides, and organofluorides, whereas offering contract analysis and manufacturing companies for prescribed drugs, agrochemicals, and specialty chemical industries.
Coming into monetary highlights, Navin Fluorine Worldwide Restricted’s income has elevated from Rs. 524 crore in Q1 FY25 to Rs. 725 crore in Q1 FY26, which has grown by 38.36 p.c. The web revenue has additionally grown by 129.41 p.c from Rs. 51 crore in Q1 FY25 to Rs. 117 crore in Q1 FY26.
Alembic Prescribed drugs Restricted
With a market capitalization of Rs. 18,584.06 crore, the shares of Alembic Prescribed drugs Restricted have been at present buying and selling at Rs. 945.45 per fairness share, down almost 0.10 p.c from its earlier day’s shut value of Rs. 946.40.
The inventory carries a one-year beta of 0.32, indicating decrease volatility in comparison with the broader market. The corporate’s ROCE and ROE stand at 13 p.c and 11.4 p.c, respectively. Alembic Prescribed drugs Restricted additionally reviews an earnings per share (EPS) of Rs. 30.7, with a debt-to-equity ratio of 0.24x, reflecting its monetary place.
Alembic Prescribed drugs Restricted was established in 1907 as Alembic Chemical Works Firm Ltd. The corporate manufactures and markets pharmaceutical merchandise, together with tablets, capsules, injections, nutritional vitamins, antibiotics, and generic formulations for home and worldwide markets, serving over 75 international locations.
Coming into monetary highlights, Alembic Prescribed drugs Restricted’s income has elevated from Rs. 1,562 crore in Q1 FY25 to Rs. 1,711 crore in Q1 FY26, which has grown by 9.54 p.c. The web revenue has additionally grown by 14.07 p.c from Rs. 135 crore in Q1 FY25 to Rs. 154 crore in Q1 FY26.
Hatsun Agro Product Restricted
With a market capitalization of Rs. 20,162.06 crore, the shares of Hatsun Agro Product Restricted have been at present buying and selling at Rs. 905.15 per fairness share, rising almost 0.57 p.c from its earlier day’s shut value of Rs. 910.30.
The inventory carries a one-year beta of 0.42, indicating decrease volatility in comparison with the broader market. The corporate’s ROCE and ROE stand at 13.1 p.c and 17 p.c, respectively. Hatsun Agro Product Restricted additionally reviews an earnings per share (EPS) of Rs. 13.6, with a debt-to-equity ratio of 1.49x, reflecting its monetary place.
Hatsun Agro Product Restricted was established in 1970 by R.G. Chandramogan. The corporate manufactures and markets dairy merchandise, together with milk, curd, ice cream, paneer, ghee, and dairy whitener underneath manufacturers like Arun, Arokya, and Hatsun for home and worldwide markets.
Coming into monetary highlights, Hatsun Agro Product Restricted’s income has elevated from Rs. 2,375 crore in Q1 FY25 to Rs. 2,535 crore in Q1 FY26, which has grown by 6.74 p.c. The web revenue has additionally grown by 12.98 p.c from Rs. 131 crore in Q1 FY25 to Rs. 148 crore in Q1 FY26.
Shriram Pistons & Rings Restricted
With a market capitalization of Rs. 11,470.79 crore, the shares of Shriram Pistons & Rings Restricted have been at present buying and selling at Rs. 2,604.05 per fairness share, down almost 0.28 p.c from its earlier day’s shut value of Rs. 2,611.40.
The inventory carries a one-year beta of 0.31, indicating decrease volatility in comparison with the broader market. The corporate’s ROCE and ROE stand at 25.7 p.c and 23.2 p.c, respectively. Shriram Pistons & Rings Restricted additionally reviews an earnings per share (EPS) of Rs. 119, with a debt-to-equity ratio of 0.21x, reflecting its monetary place.
Shriram Pistons & Rings Restricted was established in 1963, renamed in 1972. The corporate manufactures engine parts, together with pistons, piston rings, engine valves, and pins for the automotive trade, serving Unique Gear Producers (OEMs) each domestically and internationally throughout a number of car segments.
Coming into monetary highlights, Shriram Pistons & Rings Restricted’s income has elevated from Rs. 837 crore in Q1 FY25 to Rs. 963 crore in Q1 FY26, which has grown by 15.05 p.c. The web revenue has additionally grown by 15.38 p.c from Rs. 117 crore in Q1 FY25 to Rs. 135 crore in Q1 FY26.
Written By – Nikhil Naik
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/score businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Buyers should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the writer are usually not accountable for any losses brought about because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
The publish 5 Small shares with beta lower than 1 to maintain in your radar appeared first on Commerce Brains.
